A. Şahan, A. Garayev, M. Akgül, T. E. Şener, S. Evman, H. Batirel, E. Bozkurtlar, R. Ahıskalı, L. Türkeri, I. Tinay
Objective: Current guidelines for the management of renal mass recommend thoracic imaging for potential metastatic nodules. Small size of the renal mass can be associated with low metastatic potential, which might question the necessity of thoracic imaging in this patient population. This study sought to evaluate the association of thoracic imaging findings with the renal mass characteristics in patients with pathologically proven renal cell carcinoma (RCC). Materials and Methods: We performed a retrospective analysis of patients with RCC, who underwent radical/partial nephrectomy and had baseline thoracic imaging available for review. Patients with a suspicious pulmonary mass were evaluated by the Department of Thoracic Surgery. Presence of lung nodule(s) and metastasis was determined and compared with patient and renal mass characteristics. Results: A total of 215 patients were included in the study. Pulmonary nodules suspicious for malignancy were present in 26.8% of the cases and 42% of these patients underwent further examination for the presence of a pulmonary mass. Pathological examination of the pulmonary nodule revealed RCC metastasis in 80% of patients who underwent biopsy or excision of the pulmonary nodule. Of note, in the subgroup analysis according to the pathological stage of the renal mass, 19.3% of patients with pT1a disease had a suspicious pulmonary mass on thoracic imaging. Of these patients, 25% underwent further examination of the pulmonary nodule with a RCC metastasis in 66.6%. Conclusion: The presence of suspicious lung nodules in patients with RCC has metastatic potential regardless of the size of the renal mass. These findings underscore the importance of baseline thoracic imaging and vigilant further evaluation of patients in whom pulmonary nodules are identified.
{"title":"Should We Perform Thoracic Imaging for Every Patient with a Renal Mass","authors":"A. Şahan, A. Garayev, M. Akgül, T. E. Şener, S. Evman, H. Batirel, E. Bozkurtlar, R. Ahıskalı, L. Türkeri, I. Tinay","doi":"10.4274/uob.678","DOIUrl":"https://doi.org/10.4274/uob.678","url":null,"abstract":"Objective: Current guidelines for the management of renal mass recommend thoracic imaging for potential metastatic nodules. Small size of the renal mass can be associated with low metastatic potential, which might question the necessity of thoracic imaging in this patient population. This study sought to evaluate the association of thoracic imaging findings with the renal mass characteristics in patients with pathologically proven renal cell carcinoma (RCC). Materials and Methods: We performed a retrospective analysis of patients with RCC, who underwent radical/partial nephrectomy and had baseline thoracic imaging available for review. Patients with a suspicious pulmonary mass were evaluated by the Department of Thoracic Surgery. Presence of lung nodule(s) and metastasis was determined and compared with patient and renal mass characteristics. Results: A total of 215 patients were included in the study. Pulmonary nodules suspicious for malignancy were present in 26.8% of the cases and 42% of these patients underwent further examination for the presence of a pulmonary mass. Pathological examination of the pulmonary nodule revealed RCC metastasis in 80% of patients who underwent biopsy or excision of the pulmonary nodule. Of note, in the subgroup analysis according to the pathological stage of the renal mass, 19.3% of patients with pT1a disease had a suspicious pulmonary mass on thoracic imaging. Of these patients, 25% underwent further examination of the pulmonary nodule with a RCC metastasis in 66.6%. Conclusion: The presence of suspicious lung nodules in patients with RCC has metastatic potential regardless of the size of the renal mass. These findings underscore the importance of baseline thoracic imaging and vigilant further evaluation of patients in whom pulmonary nodules are identified.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"90-93"},"PeriodicalIF":0.2,"publicationDate":"2016-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bilateral Spermatocele Following Radical Retropubic Prostatectomy: Case Report","authors":"H. C. Aybal, T. N. Yıkılmaz, E. Öztürk, H. Başar","doi":"10.4274/UOB.719","DOIUrl":"https://doi.org/10.4274/UOB.719","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"127-128"},"PeriodicalIF":0.2,"publicationDate":"2016-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Çelik, Ozan Bozkurt, H. Yıldız, O. Demir, B. Tuna, K. Yorukoglu, G. Aslan
Radikal prostatektomi (RP) lokalize prostat kanserinde küratif tedavi yöntemlerinden biridir (1,2). RP sonrası patolojide ekstraprostatik yayılım, cerrahi sınır pozitifliği ve lenf nodu pozitifliği gibi lokal ileri evre hastalık bulguları saptanan prostat kanserli hastalarda ek tedavi gereksinimi doğabilmektedir. Bu yüzdendir ki radikal tedavi öncesi lokal ileri hastalığı tahmin edebilmek adına öngörü faktörleri araştırılmış ve risk grupları oluşturulmuştur (1,2). Bu faktörlerden en önemlileri hastanın klinik evresi, prostat iğne biyopsisi öncesi prostat spesifik antijen (PSA) değeri ve prostat iğne biyopsi Gleason skorudur (3,4). Bu üç faktörün birlikte değerlendirilerek radikal tedaviden fayda/zarar oranını öngörebilmek adına oluşturulan ve en çok kullanılan sınıflama D’Amico risk sınıflamasıdır. Bu faktörlerin
{"title":"Significance of Pretreatment Testosterone Levels in Prostate Cancer Risk Groups","authors":"S. Çelik, Ozan Bozkurt, H. Yıldız, O. Demir, B. Tuna, K. Yorukoglu, G. Aslan","doi":"10.4274/UOB.699","DOIUrl":"https://doi.org/10.4274/UOB.699","url":null,"abstract":"Radikal prostatektomi (RP) lokalize prostat kanserinde küratif tedavi yöntemlerinden biridir (1,2). RP sonrası patolojide ekstraprostatik yayılım, cerrahi sınır pozitifliği ve lenf nodu pozitifliği gibi lokal ileri evre hastalık bulguları saptanan prostat kanserli hastalarda ek tedavi gereksinimi doğabilmektedir. Bu yüzdendir ki radikal tedavi öncesi lokal ileri hastalığı tahmin edebilmek adına öngörü faktörleri araştırılmış ve risk grupları oluşturulmuştur (1,2). Bu faktörlerden en önemlileri hastanın klinik evresi, prostat iğne biyopsisi öncesi prostat spesifik antijen (PSA) değeri ve prostat iğne biyopsi Gleason skorudur (3,4). Bu üç faktörün birlikte değerlendirilerek radikal tedaviden fayda/zarar oranını öngörebilmek adına oluşturulan ve en çok kullanılan sınıflama D’Amico risk sınıflamasıdır. Bu faktörlerin","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"98-102"},"PeriodicalIF":0.2,"publicationDate":"2016-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sentinel Lymph Node Biopsy in Lymphadenectomy for Prostate Cancer","authors":"C. Acar, H. Poel","doi":"10.4274/UOB.625","DOIUrl":"https://doi.org/10.4274/UOB.625","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"69-75"},"PeriodicalIF":0.2,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Ceylan, Volkan Şen, S. Polat, B. Gunlusoy, T. Değirmenci, Y. K. Topcu, D. Bolat, Z. Kozacıoğlu
{"title":"The Incidence of Prostate Adenocarcinoma in Patients Who Underwent Cystoprostatectomy for Invasive Baldder Cancer and Histopathological Examination","authors":"Y. Ceylan, Volkan Şen, S. Polat, B. Gunlusoy, T. Değirmenci, Y. K. Topcu, D. Bolat, Z. Kozacıoğlu","doi":"10.4274/uob.647","DOIUrl":"https://doi.org/10.4274/uob.647","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"61-64"},"PeriodicalIF":0.2,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Son yıllarda, yeni tanı almış metastatik prostat kanseri hastalarında başlangıç tedavisi olarak androjen yoksunluk tedavisi (AYT) ile farklı kemoterapi kombinasyonlarının uygulanmasına dair çalışmalar yayınlanmış ve geçtiğimiz yıl içinde de söz konusu hasta grubunda AYT ile birlikte uygulanan dosetaksel kemoterapisinin olası etkileri, Kuzey Amerika (CHAARTED) ve Avrupa (GETUG-AFU-15) kaynaklı 2 çok merkezli randomize çalışmada değerlendirilmiştir. Bu derlemede kastrasyona duyarlı metastatik prostat kanserinde başlangıç tedavisi olarak kemohormonal tedaviye ait çalışmaların gözden geçirilmesi amaçlanmıştır. CHAARTED çalışmasının yeni bulguları, AYT ile birlikte uygulanan dosetaksel tedavisinin genel sağkalımı sadece AYT’ye oranla anlamlı olarak arttırdığını ve bu etkinin özellikle yüksek volümlü metastatik hastalığa sahip hastalarda 17 aylık medyan genel sağkalım artışı şeklinde izlendiğini göstermektedir. GETUG çalışmasında ise; genel sağkalım açısından her iki grup arasında fark saptanmamıştır ancak biyokimyasal progresyonsuz sağkalımda ve klinik progresyonsuz sağkalımda kombinasyon tedavisi lehine anlamlı artış izlenmiştir. Metastatik prostat kanseri tanısı alan hastalarda başlangıç tedavisi olarak kemoterapi ve AYT kombinasyon tedavisinin uygulanması, özellikle “yüksek volümlü” hastalığa sahip olan hasta grubunda ümit verici gözükmektedir. Anahtar Kelimeler: Metastatik prostat kanseri, kemoterapi, hormonal tedavi, kombinasyon In recent years, studies have been reported about the combination of androgen deprivation therapy (ADT) and different chemotherapy modalities as the initial therapy in newly-diagnosed patients with hormone-sensitive metastatic prostate cancer and recently, possible effects of docataxel chemotherapy in combination with ADT was evaluated in the 2 multi-institutional randomized trials from North America (CHAARTED) and Europe (GETUG-AFU-15). We reviewed the data for the current use of chemo-hormonal therapy as the initial treatment modality in castration-sensitive metastatic prostate cancer. New findings of CHAARTED trial showed that combination of ADT with docetaxel chemotherapy conferred a significant median over-all survival benefit over ADT alone and patients with high-volume disease derived a 17-month gain in median over-all survival. However in GETUG trial, while no over-all survival benefit was observed between two groups however combination therapy was associated with an improvement in biochemical and clinical progression-free survivals. The combination of docetaxel-based chemotherapy with ADT as the initial treatment seems as a promising treatment alternative in patients with hormone-sensitive metastatic prostate cancer, especially in patients with “high-volume” disease.
{"title":"A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”","authors":"I. Tinay, L. Türkeri","doi":"10.4274/uob.434","DOIUrl":"https://doi.org/10.4274/uob.434","url":null,"abstract":"Son yıllarda, yeni tanı almış metastatik prostat kanseri hastalarında başlangıç tedavisi olarak androjen yoksunluk tedavisi (AYT) ile farklı kemoterapi kombinasyonlarının uygulanmasına dair çalışmalar yayınlanmış ve geçtiğimiz yıl içinde de söz konusu hasta grubunda AYT ile birlikte uygulanan dosetaksel kemoterapisinin olası etkileri, Kuzey Amerika (CHAARTED) ve Avrupa (GETUG-AFU-15) kaynaklı 2 çok merkezli randomize çalışmada değerlendirilmiştir. Bu derlemede kastrasyona duyarlı metastatik prostat kanserinde başlangıç tedavisi olarak kemohormonal tedaviye ait çalışmaların gözden geçirilmesi amaçlanmıştır. CHAARTED çalışmasının yeni bulguları, AYT ile birlikte uygulanan dosetaksel tedavisinin genel sağkalımı sadece AYT’ye oranla anlamlı olarak arttırdığını ve bu etkinin özellikle yüksek volümlü metastatik hastalığa sahip hastalarda 17 aylık medyan genel sağkalım artışı şeklinde izlendiğini göstermektedir. GETUG çalışmasında ise; genel sağkalım açısından her iki grup arasında fark saptanmamıştır ancak biyokimyasal progresyonsuz sağkalımda ve klinik progresyonsuz sağkalımda kombinasyon tedavisi lehine anlamlı artış izlenmiştir. Metastatik prostat kanseri tanısı alan hastalarda başlangıç tedavisi olarak kemoterapi ve AYT kombinasyon tedavisinin uygulanması, özellikle “yüksek volümlü” hastalığa sahip olan hasta grubunda ümit verici gözükmektedir. Anahtar Kelimeler: Metastatik prostat kanseri, kemoterapi, hormonal tedavi, kombinasyon In recent years, studies have been reported about the combination of androgen deprivation therapy (ADT) and different chemotherapy modalities as the initial therapy in newly-diagnosed patients with hormone-sensitive metastatic prostate cancer and recently, possible effects of docataxel chemotherapy in combination with ADT was evaluated in the 2 multi-institutional randomized trials from North America (CHAARTED) and Europe (GETUG-AFU-15). We reviewed the data for the current use of chemo-hormonal therapy as the initial treatment modality in castration-sensitive metastatic prostate cancer. New findings of CHAARTED trial showed that combination of ADT with docetaxel chemotherapy conferred a significant median over-all survival benefit over ADT alone and patients with high-volume disease derived a 17-month gain in median over-all survival. However in GETUG trial, while no over-all survival benefit was observed between two groups however combination therapy was associated with an improvement in biochemical and clinical progression-free survivals. The combination of docetaxel-based chemotherapy with ADT as the initial treatment seems as a promising treatment alternative in patients with hormone-sensitive metastatic prostate cancer, especially in patients with “high-volume” disease.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"65-68"},"PeriodicalIF":0.2,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70974794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Aydos, A. Erdoğan, M. Şambel, Noyan Can Akdur, S. Oner, M. Kılıç
{"title":"Cystic Nephroma in Elderly Male Patient","authors":"M. Aydos, A. Erdoğan, M. Şambel, Noyan Can Akdur, S. Oner, M. Kılıç","doi":"10.4274/UOB.591","DOIUrl":"https://doi.org/10.4274/UOB.591","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"83-85"},"PeriodicalIF":0.2,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70976675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Üçer, C. Akdeniz, M. Yuksel, G. Temeltaş, T. Müezzinoğlu
{"title":"Partial Urethrectomy for Female Urethral Transitional Epithelial Cell Carcinoma","authors":"O. Üçer, C. Akdeniz, M. Yuksel, G. Temeltaş, T. Müezzinoğlu","doi":"10.4274/uob.574","DOIUrl":"https://doi.org/10.4274/uob.574","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"80-82"},"PeriodicalIF":0.2,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70976771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Histopathologic Parameters Accompanying by Incidental Prostate Cancer","authors":"A. Ihvan, C. Ediz, N. Koç","doi":"10.4274/UOB.627","DOIUrl":"https://doi.org/10.4274/UOB.627","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"15 1","pages":"48-51"},"PeriodicalIF":0.2,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Çelik, Ozan Bozkurt, H. Yıldız, O. Demir, B. Tuna, K. Yorukoglu, G. Aslan
{"title":"Association between Hormonal Evaluation Before Prostate Needle Biopsy and Locally Advanced Prostate Cancer","authors":"S. Çelik, Ozan Bozkurt, H. Yıldız, O. Demir, B. Tuna, K. Yorukoglu, G. Aslan","doi":"10.4274/UOB.638","DOIUrl":"https://doi.org/10.4274/UOB.638","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"34 1","pages":"52-56"},"PeriodicalIF":0.2,"publicationDate":"2016-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：